Nextgen Biomed (TASE:NXGN)

Nextgen-Biomed is a pharmaceutical company holding 98.6% of Dermipsor which develops topical treatment for Psoriasis. Dermipsor was founded in 2004 based on the invention of Dr. Avikam Harel, head of pediatric dermatology at Ichilov Hospital. The company completed phase IIB feasibility study, accomplished preparing the FDA outline for Phase III clinical trial and is gearing towards Phase II/III clinical trial.